Compare Amylx Pharmaceuticals Inc (AMLX) vs Gold Fields Limited (GFI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Gold Fields Limited — how do they compare? Amylx Pharmaceuticals Inc trades at $22.57 (market cap $2.60B), while Gold Fields Limited trades at $39.02 (market cap $36.57B). The key difference: Gold Fields Limited is far larger — about 14.1× Amylx Pharmaceuticals Inc's market cap, and Gold Fields Limited pays a 5.7% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | GFI | |
|---|---|---|
Market Cap | $2.60B | $36.57B |
Sector | Health | Basic Materials |
52-Week High | $24.19 | $61.52 |
52-Week Low | $7.82 | $29.31 |
Enterprise Value | $2.36B | $38.01B |
Dividend Yield | — | 5.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.35, down 1.18% on the day, with strong analyst support (90.9% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum with moving averages supporting upward movement, though RSI levels indicate potential overbought conditions. Recent Q2 2026 earnings missed expectations with a loss of $0.39 per share, but the company maintains significant cash reserves through 2028 and anticipates key Phase 3 trial results for avexitide in late August/September 2026.
The investment case hinges on successful clinical trial outcomes and future revenue generation, with current negative profitability metrics offset by strong institutional backing and promising pipeline catalysts. Key risks include clinical trial failures, ongoing financial losses, and competitive pressures in the biotech sector.
Gold Fields (GFI) trades at $39.53, down 1.84% today, with strong fundamentals including 40.76% net income margin and 52.33% ROE. Recent earnings show mixed results with Q1 2025 beating expectations but Q2 and Q4 2025 missing. Technical indicators show bullish moving averages but overbought RSI levels. The company demonstrates robust cash flow growth with 2025 projections showing $919M net cash flow.
GFI presents a compelling value opportunity with a 10.34 P/E ratio and $52 consensus price target offering 31% upside. Strong profitability metrics and institutional accumulation support the bullish case, though recent earnings misses and elevated debt levels warrant monitoring. The gold mining sector benefits from sustained $4,000+ gold prices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →
